

---

*primary studies - published RCT*

## **Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis.**

**Code:** PM11389575

**Year:** 2001

**Date:** 2001

**Author:** Ziebach R

### **Study design (if review, criteria of inclusion for studies)**

Dual intervention cross-over trial over 4 days

### **Participants**

17 participants (6 males), age range 7 - 33 years, 16 participants analysed

### **Interventions**

Randomised to single dose nebulised placebo, salbutamol 5 mg, ipratropium 0.25 mg or combination

### **Outcome measures**

Changes in spirometry (FVC, FEV1, FEF25-75, FEF50, TGV, Raw ) measured at baseline and 30 minutes later

### **Main results**

The mean forced expiratory volume in the first second improved significantly (adjusted P-value

### **Authors' conclusions**

in CF patients bronchodilator therapy with sympathomimetic agents is usually sufficient. Only in cases with proven additional benefit from inhalation by anticholinergics should combination therapy be recommended.

<http://dx.doi.org/10.1002/ppul.1071>

### **See also**

Pediatr Pulmonol. 2001 Jun;31(6):431-5.

### **Keywords**

Adolescent; Adult; Albuterol; Biomarker; Bronchodilator Agents; Child; Combined Modality Therapy; Inhalation OR nebulised; Ipratropium; non pharmacological intervention - diagn; pharmacological\_intervention; placebo; Salbutamol; Adrenergic beta-Agonists; Respiratory System Agents; Anticholinergic Agents;